Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Indian J Med Sci ; 2010 Aug; 64(8) 363-372
Article Dans Anglais | IMSEAR | ID: sea-145554

Résumé

Background: Airway hyperresponsiveness (AHR) is the most characteristic feature of asthma, which is reported in COPD patients and smokers. Increased airway responsiveness to ί-agonists is also demonstrated in asthmatics as well as smokers. However, there is no report regarding AHR to ί-agonist drugs in COPD patients. Therefore, in this study pharmacologic bronchodilation response to salbutamol in COPD patients was examined. Materials and Methods: The threshold concentrations of inhaled salbutamol required for a 20% change in forced expiratory flow in 1 sec (FEV 1 ) as PC 20 , or a 35% change in specific airway conductance (sGaw) as PC 35 was measured in 14 COPD patients and 14 normal subjects. Results: Airway responsiveness to salbutamol in COPD patients (PC 20 = 14.14 ± 1.62 and PC 35 = 9.70 ± 1.48 mg/l) was significantly lower than normal subjects (PC 20 = 224.57 ± 16.62 and PC 35 = 81.87 ± 8.16 mg/l, P < 0.001 for both cases). The values of FEV 1 and sGaw in COPD patients (56.43 ± 14.45 and 0.081 ± 0.120 respectively) were significantly lower than those of normal subjects (104.07 ± 5.72 and 0.194 ± 0.041 respectively), (P < 0.001 for FEV 1 and P < 0.005 for sGaw). There was a significant correlation between FEV 1 with PC 20 salbutamol (r = 0.862, P < 0.001). The correlations between PC 20 and PC 35 was also statistically significant (r = 0.862, P < 0.001). Conclusion: These results showed increased airway responsiveness of most COPD patients to salbutamol which was highly correlated to airway caliber.


Sujets)
Adulte , Sujet âgé , Remodelage des voies aériennes/effets des médicaments et des substances chimiques , Résistance des voies aériennes/traitement médicamenteux , Salbutamol/pharmacocinétique , Salbutamol/pharmacologie , Antiasthmatiques/pharmacologie , Antiasthmatiques/usage thérapeutique , Asthme/traitement médicamenteux , Asthme/physiopathologie , Bronches/effets des médicaments et des substances chimiques , Bronches/pharmacologie , Bronches/physiologie , Hyperréactivité bronchique/pharmacologie , Bronchodilatateurs/pharmacocinétique , Bronchodilatateurs/pharmacologie , Patients , Broncho-pneumopathie chronique obstructive/traitement médicamenteux , Fumer/effets indésirables , Fumer/complications
SÉLECTION CITATIONS
Détails de la recherche